Track Alkermes plc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Alkermes plc ALKS Open Alkermes plc in new tab

37.19 USD
P/E
41.64
EPS
0.90
P/B
3.56
ROE
9.36
Beta
0.26
Target Price
46.00 USD
Alkermes plc logo

Alkermes plc

🧾 Earnings Recap – Q1 2026

Alkermes shares rose 3.4% post-earnings, reflecting investor approval of robust proprietary product sales growth and early contributions from the recently acquired sleep medicine asset, LUMRYZ.

  • Proprietary product net sales grew 38% year-over-year to $338.1 million, driven by strong demand across psychiatry and addiction franchises.
  • VIVITROL sales reached $112.4 million, supported by favorable localized market dynamics; 2026 guidance reaffirmed at $460–480 million.
  • Psychiatry portfolio net sales included ARISTADA at $93.8 million and LYBALVI at $92.4 million, with LYBALVI TRX growing 21% year-over-year; full-year sales guidance maintained.
  • Favorable gross-to-net adjustments contributed approximately $14 million of upside in Q1, primarily from improved patient mix.
  • Integration of Avadel and the LUMRYZ launch added six weeks of commercial contribution and established Alkermes’ presence in the sleep medicine market ahead of future pipeline opportunities.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 4, 2026
P/E41.64
EPS0.90
Book Value10.52
Price to Book3.56
Debt/Equity90.30
% Insiders1.418%
Growth
Revenue Growth0.28%
Earnings Growth-0.67%
Estimates
Forward P/E15.92
Forward EPS2.35
Target Mean Price46.00

DCF Valuation

Tweak assumptions to recompute fair value for Alkermes plc (ALKS)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Alkermes plc Logo Alkermes plc Analysis (ALKS)

Ireland Health Care Official Website Stock

Is Alkermes plc a good investment? Alkermes plc (ALKS) is currently trading at 37.19 USD. Market analysts have a consensus price target of 46.00 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 41.64. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Alkermes plc is expected to release its next earnings report on Aug. 4, 2026. The market consensus estimate for Forward EPS is 2.35.

Investor FAQ

Does Alkermes plc pay a dividend?

No, it does not currently pay a dividend.

What asset class is Alkermes plc?

Alkermes plc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 4, 2026. The company currently has a trailing EPS of 0.90.

Company Profile

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Exchange Ticker
NMS (United States) ALKS

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
May 15, 2000 2.000000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion